MA46642A - Promédicaments d'inhibiteurs de la kallicréine - Google Patents

Promédicaments d'inhibiteurs de la kallicréine

Info

Publication number
MA46642A
MA46642A MA046642A MA46642A MA46642A MA 46642 A MA46642 A MA 46642A MA 046642 A MA046642 A MA 046642A MA 46642 A MA46642 A MA 46642A MA 46642 A MA46642 A MA 46642A
Authority
MA
Morocco
Prior art keywords
kallicrein
medicinal products
inhibitor
inhibitor medicinal
products
Prior art date
Application number
MA046642A
Other languages
English (en)
Inventor
Yarlagadda S Babu
Venkat R Chintareddy
Pravin L Kotian
V Satish Kumar
Lakshminarayana Vogeti
Weihe Zhang
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MA46642A publication Critical patent/MA46642A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
MA046642A 2016-10-31 2017-10-27 Promédicaments d'inhibiteurs de la kallicréine MA46642A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662415202P 2016-10-31 2016-10-31

Publications (1)

Publication Number Publication Date
MA46642A true MA46642A (fr) 2021-04-21

Family

ID=62025466

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046642A MA46642A (fr) 2016-10-31 2017-10-27 Promédicaments d'inhibiteurs de la kallicréine

Country Status (10)

Country Link
US (2) US10759759B2 (fr)
EP (1) EP3532057B1 (fr)
JP (1) JP7128181B2 (fr)
AU (1) AU2017348305B2 (fr)
CA (1) CA3041058A1 (fr)
DK (1) DK3532057T3 (fr)
ES (1) ES2942285T3 (fr)
IL (1) IL266223B2 (fr)
MA (1) MA46642A (fr)
WO (1) WO2018081513A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3532057T3 (da) 2016-10-31 2023-02-20 Biocryst Pharm Inc Prodrugs af kallikreininhibitorer
CN115835860A (zh) * 2020-06-12 2023-03-21 树顶分子生技股份有限公司 用于治疗非酒精性脂肪性肝病和非酒精性脂肪性肝炎的带有碳酸酯的紫檀芪氨基酸的新型类似物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (fr) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Support pour medicaments a liberation progressive
DE69110787T2 (de) 1990-02-28 1996-04-04 Medtronic Inc Intraluminale prothese mit wirkstoffeluierung.
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
MXPA03009130A (es) * 2000-10-20 2004-02-26 Biocryst Pharm Inc Compuestos de biarilo que funcionan como inhibidores de proteasa serina.
PT1383731E (pt) 2001-04-06 2009-11-03 Biocryst Pharm Inc Compostos de biarilo como inibidores de serina-protease
AU2003245060A1 (en) 2002-06-27 2004-01-19 Lg Life Sciences Ltd. Peptidic thrombin inhibitor compound
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
GB0301938D0 (en) 2003-01-28 2003-02-26 Biochemie Gmbh Organic compounds
ES2376130T3 (es) 2006-10-06 2012-03-09 Toyama Chemical Co., Ltd. Composición farmacéutica que contiene un derivado de fenilamidina y método de utilización de la composición farmacéutica en combinación con un agente antifúngico.
KR20100026641A (ko) 2008-09-01 2010-03-10 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
EP2693876B1 (fr) 2011-04-08 2020-01-15 Sphaera Pharma Pte. Ltd Réactifs de méthylformyle substitué et procédé d'utilisation de ceux-ci pour modifier des propriétés physicochimiques et/ou pharmacocinétiques de composés
EP3189840B1 (fr) 2011-07-28 2021-05-19 Kempharm, Inc. Promédicaments de methylphenidate, procédés pour leur production et leur utilisation
TWI601725B (zh) 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
EP2934507B1 (fr) 2012-12-21 2017-05-31 ratiopharm GmbH Promédicaments du fumarate de monométhyle (mmf)
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
KR102256242B1 (ko) 2014-02-07 2021-05-26 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물
WO2016029214A1 (fr) * 2014-08-22 2016-02-25 Biocryst Pharmaceuticals, Inc. Compositions et utilisations de dérivés d'amidine
WO2016029216A2 (fr) 2014-08-22 2016-02-25 Biocryst Pharmaceuticals, Inc. Procédé de production de dérivés d'amidine
DK3532057T3 (da) 2016-10-31 2023-02-20 Biocryst Pharm Inc Prodrugs af kallikreininhibitorer

Also Published As

Publication number Publication date
JP2019535688A (ja) 2019-12-12
US11618731B2 (en) 2023-04-04
US20190382344A1 (en) 2019-12-19
AU2017348305A1 (en) 2019-05-30
EP3532057B1 (fr) 2022-12-21
AU2017348305B2 (en) 2022-04-21
JP7128181B2 (ja) 2022-08-30
ES2942285T3 (es) 2023-05-31
DK3532057T3 (da) 2023-02-20
IL266223B2 (en) 2024-04-01
IL266223A (en) 2019-06-30
IL266223B1 (en) 2023-12-01
EP3532057A4 (fr) 2020-07-01
US10759759B2 (en) 2020-09-01
EP3532057A1 (fr) 2019-09-04
CA3041058A1 (fr) 2018-05-03
WO2018081513A1 (fr) 2018-05-03
US20210198204A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA44725A (fr) Formulations d'un inhibiteur de lsd1
DK3935068T3 (da) Abirateron-prodrugs
BR112017001684A2 (pt) preparação de produto de proteína de pulso ("yp810")
DK3634377T3 (da) Farmaceutisk formulering
MA49006A (fr) Inhibiteurs d'ip6k
ES2841649T5 (es) Composición farmacéutica
MA44987A (fr) Formulations de médicaments améliorées
CL2019000563S1 (es) Envase y dispendio de medicamentos. (divisional solicitud 201800718)
DK3601277T3 (da) Farmaceutisk formulering
MA46642A (fr) Promédicaments d'inhibiteurs de la kallicréine
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
ES1141665Y (es) Dispositivo para la administración de un producto cosmético
FR3016128B1 (fr) Tete de distribution et d'application.
DK3728220T3 (da) Farmaceutiske forbindelser
IT201700090331A1 (it) "lopemide"
UA36577S (uk) Етикетка для упаковки лікарського засобу «гропівірін»
IT201700071679A1 (it) Remembebe'
UA35313S (uk) Сувенірний виріб «бандура»
UA35311S (uk) Сувенірний виріб «бандура»
UA35447S (uk) Етикетка для фармацевтичного засобу
UA34521S (uk) Упаковка для лікарського засобу «урофосцин»
UA37338S (uk) Розгортка упаковки лікарського засобу
UA37339S (uk) Розгортка упаковки лікарського засобу
UA36043S (uk) Упаковка-етикетка для солодощів «фрукфетта»